PAVmed Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>PAVmed Inc. has submitted its 2023 annual report (10-K), detailing financial and operational information for the fiscal year ending December 31, 2023.</b>

AI Summary

PAVmed Inc. (PAVM) filed a Annual Report (10-K) with the SEC on March 25, 2024. PAVmed Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is 360 Madison Avenue, New York, NY. PAVmed Inc. was formerly known as PAXmed Inc., with a name change date of November 5, 2014. The filing includes details on common stock, Series Z warrants, and Series B convertible preferred stock.

Why It Matters

For investors and stakeholders tracking PAVmed Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of PAVmed Inc.'s financial performance, business operations, and risk factors for the 2023 fiscal year, crucial for investors to assess the company's health and future prospects. The document contains detailed financial statements and disclosures, including information on equity, warrants, and convertible preferred stock, which are essential for understanding the company's capital structure and potential dilution.

Risk Assessment

Risk Level: medium — PAVmed Inc. shows moderate risk based on this filing. The company's financial health and operational status are detailed in this 10-K, but specific financial performance metrics like revenue, net income, or debt levels are not provided in the extracted header information, requiring a deeper dive into the full document for a complete assessment.

Analyst Insight

Review the full 10-K filing for detailed financial statements, revenue figures, net income, debt levels, and management's discussion and analysis to understand PAVmed Inc.'s performance and outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-25 — Filing Date (As of date)
• 001-37685 — SEC File Number (SEC file number)

Key Players & Entities

• PAVmed Inc. (company) — Filer name
• PAVM (company) — Ticker symbol
• PAXmed Inc. (company) — Former company name
• 360 Madison Avenue (location) — Business address
• New York (location) — Business address city
• DE (location) — State of incorporation

FAQ

Industry Context

PAVmed Inc. operates in the surgical and medical instruments & apparatus industry (SIC code 3841). This sector involves the development and manufacturing of medical devices and equipment.

Regulatory Implications

As a publicly traded company in the US, PAVmed Inc. is subject to the reporting requirements of the Securities and Exchange Commission (SEC) under the 1934 Act, including the filing of annual reports on Form 10-K.

What Investors Should Do

1. Access and thoroughly review the full 10-K filing for detailed financial statements, including revenue, expenses, assets, liabilities, and cash flows.
2. Analyze the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into the company's performance drivers and future outlook.
3. Examine the 'Risk Factors' section to understand potential challenges and uncertainties that could impact PAVmed Inc.'s business and stock price.

Key Dates

• 2023-12-31: Fiscal Year End — The end date for the reporting period covered by the 10-K.
• 2024-03-25: Filing Date — The date the 10-K report was officially filed with the SEC.

Year-Over-Year Comparison

This filing represents the annual report for the fiscal year 2023, providing updated financial and operational data compared to previous filings.

Key Financial Figures

• $0.001 — nge on which Registered Common Stock, $0.001 par value per share PAVM The NASDAQ
• $6.12 — are of the registrant's common stock of $6.12 on such date. As of March 21, 2024, t
• $60 billion — le U.S. market opportunity approximates $60 billion based on an effective Medicare payment
• $1,938 — sed on an effective Medicare payment of $1,938 and the estimated 30 million U.S. patie
• $100 million — s follows: 5% of net sales of less than $100 million per year; and 8% of net sales greater t
• $50,000 — mum annual royalty payments as follows: $50,000 per year, beginning January 1 following
• $150,000 — commercial sale of a licensed product; $150,000 per year, if net sales of a licensed pr
• $25 million — net sales of a licensed product exceed $25 million in a year; $300,000 per year, if net sa
• $300,000 — d product exceed $25 million in a year; $300,000 per year, if net sales of a licensed pr
• $50 million — net sales of a licensed product exceed $50 million in a year; and $600,000 per year, if ne
• $600,000 — oduct exceed $50 million in a year; and $600,000 per year, if net sales of a licensed pr

Filing Documents

• form10-k.htm (10-K) — 2887KB
• ex4-1.htm (EX-4.1) — 59KB
• ex21-1.htm (EX-21.1) — 13KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• ex97-1.htm (EX-97.1) — 58KB
• 0001493152-24-011172.txt (&nbsp;) — 12479KB
• pavm-20231231.xsd (EX-101.SCH) — 68KB
• pavm-20231231_cal.xml (EX-101.CAL) — 91KB
• pavm-20231231_def.xml (EX-101.DEF) — 349KB
• pavm-20231231_lab.xml (EX-101.LAB) — 575KB
• pavm-20231231_pre.xml (EX-101.PRE) — 495KB
• form10-k_htm.xml (XML) — 2405KB

Business

Business 1 Item 1A Risk Factors 16 Item 1B. Unresolved Staff Comments 34 Item 1C. Cybersecurity 35 Item 2. Property 35 Item 3. Legal Proceedings 35 Item 4. Mine Safety Disclosures 35 PART II Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 36 Item 6. [Reserved] 36 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 7A. Quantitative and Qualitative Disclosure About Market Risk 47 Item 8. Financial 48 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 48 Item 9A. Controls and Procedures 48 Item 9B. Other Information 48 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 48 PART III Item 10. Directors, Executive Officers, and Corporate Governance 49 Item 11. Executive Compensation 49 Item 12. Security 49 Item 13. Certain Relationships and Related Transactions and Director Independence 49 Item 14. Principal Accountant Fees and Services 49 PART IV Item 15. Exhibits and Financial Statement Schedules 50 Item 16. Form 10-K Summary 51 i FORWARD-LOOKING This Annual Report on Form 10-K (this "Form 10-K"), including the discussion and analysis of our consolidated financial condition and results of operations set forth under Item 7 of this Form 10-K, contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form 10-K, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words "may," "will," "should," "expects," "plans,"

View Full Filing

View this 10-K filing on SEC EDGAR